DIM
CLDI icon

DLK Investment Management’s Calidi Biotherapeutics CLDI Stock Holding History

DLK Investment Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-173
Closed -$4.16K – 114
2024
Q2 		$4.16K Buy
+173
New +$5.53K ﹤0.01% 108

Other funds holding CLDI

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $559M AUM 19.86% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

DLK Investment Management's CLDI Position: Q3 2024 in Review

DLK Investment Management sold out of Calidi Biotherapeutics (CLDI) in Q3 2024, closing a stake of 173 shares — an estimated $4.16K sold.

DLK Investment Management first reported a position in CLDI in Q2 2024 and held it in 1 quarter. The position peaked at $4.16K in Q2 2024. 20 funds tracked by Wall St. Rank hold CLDI as of Q3 2024.

  • DLK Investment Management reported no remaining Calidi Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • DLK Investment Management sold 173 Calidi Biotherapeutics shares in Q3 2024, an estimated $4.16K.
  • DLK Investment Management first reported a position in Calidi Biotherapeutics in Q2 2024 and held it in 1 quarter.
  • DLK Investment Management's Calidi Biotherapeutics position peaked at $4.16K in Q2 2024.
  • 20 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2024.

Based on DLK Investment Management's 13F filing for Q3 2024, filed 9 Oct 2024.